Soleno Therapeutics (SLNO) Non-Current Assets (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Non-Current Assets of $282.0 million for Q1 2026, up 2973.03% year-over-year from $9.2 million in Q1 2025, and up 35.57% quarter-over-quarter from $208.0 million in Q4 2025.
Soleno Therapeutics (SLNO) Non-Current Assets (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Non-Current Assets for 14 consecutive years, with $282.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 2973.03% year-over-year to $282.0 million; the TTM figure through Mar 2026 stood at $570.6 million (up 370.02% YoY), while the FY2025 annual figure was $208.0 million, up 460.95% from the prior year.
- Non-Current Assets grew to $282.0 million in Q1 2026 per SLNO's latest filing, from $208.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $282.0 million in Q1 2026 and bottomed at $9.2 million in Q1 2025.
- Historically, Non-Current Assets has averaged $46.9 million across 5 years, with a median of $12.6 million in 2022.
- Annual changes were most pronounced in 2025 — Non-Current Assets slumped 57.64% — and 2026, when it surged 2973.03%.
- Soleno Therapeutics' Non-Current Assets stood at $10.8 million in 2022, then fell by 13.98% to $9.3 million in 2023, then jumped by 297.33% to $37.1 million in 2024, then soared by 460.95% to $208.0 million in 2025, then surged by 35.57% to $282.0 million in 2026.
- Business Quant data shows SLNO's Non-Current Assets at $282.0 million in Q1 2026, $208.0 million in Q4 2025, and $65.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 282.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 282.01 Mn |
| Dec 31, 2025 | 208.02 Mn |
| Sep 30, 2025 | 65.04 Mn |
| Jun 30, 2025 | 15.52 Mn |
| Mar 31, 2025 | 9.18 Mn |
| Dec 31, 2024 | 37.08 Mn |
| Sep 30, 2024 | 38.51 Mn |
| Jun 30, 2024 | 36.63 Mn |
| Mar 31, 2024 | 17.61 Mn |
| Dec 31, 2023 | 9.33 Mn |
| Sep 30, 2023 | 9.89 Mn |
| Jun 30, 2023 | 10.45 Mn |
| Mar 31, 2023 | 10.41 Mn |
| Dec 31, 2022 | 10.85 Mn |
| Sep 30, 2022 | 11.41 Mn |
| Jun 30, 2022 | 11.97 Mn |
| Mar 31, 2022 | 12.57 Mn |
| Dec 31, 2021 | 13.13 Mn |
| Sep 30, 2021 | 13.68 Mn |
| Jun 30, 2021 | 14.23 Mn |